11. Pan N, Wu Y, Chen R, et al. Neuroimaging markers of stimulant and non-stimulant treatment in ADHD: a comparative analysis. Psychol Med. 2024; 54:1889 – 1902.
12. De Crescenzo F, Cortese S, Adamo N, et al. Pharmacological and nonpharmacological treatment of adults with ADHD: a meta-review. Evid Based Ment Health. 2016; 19( 4): 164 – 171.
13. Stevens L, Zhang W, Peck L, et al. Nutritional interventions in ADHD: a review of current evidence. J Altern Complement Med. 2019; 25( 2): 112 – 118.
14. Howard AL, Robinson M, Smith GJ, Ambrosini JL, Piek JP, Oddy WH. ADHD is associated with a‘ western’ dietary pattern in adolescents. J Pediatr Psychol. 2010; 35( 7): 758 – 768.
15. Safer DJ. Growth effects of stimulant medication for ADHD. Pediatrics. 1992; 89( 4): 784 – 789.
16. Juneja M, Jain R, Singh V, Mallika V. Evaluation of serum ferritin in children with attention deficit hyperactivity disorder. Indian Pediatr. 2010; 47( 11): 871 – 876.
17. Beard JL, Connor JR. Iron status and neural functioning. Am J Clin Nutr. 2003; 77( 4): 964 – 970.
18. Cortese S, Konofal E, Bernardina BD, Mouren MC. Sleep disturbances in ADHD: associations with ferritin levels. Prog Neuropsychopharmacol Biol Psychiatry. 2009; 33( 4): 684 – 692.
19. Akhondzadeh S, Mohammadi MR, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention-deficit / hyperactivity disorder in children: a randomized clinical trial. BMC Psychiatry. 2004; 4:9.
20. Starobrat-Hermelin B, Kozielec T. The role of magnesium in children with ADHD. Magnes Res. 1997; 10( 2): 149 – 156.
21. Nogovitsina OR, Levitina EV. Magnesium deficiency in children with ADHD and the efficacy of magnesium supplementation. Magnes Res. 2005; 18( 3): 327 – 334.
22. Kozielec T, Starobrat-Hermelin B. Assessment of magnesium and zinc in children with ADHD. Acta Med Pol. 1997; 38( 4): 289 – 295.
23. Cortese S, Moreira-Maia CR, Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. J Atten Disord. 2016; 20( 3): 239 – 248.
24. Mohammadpour N, Jazayeri S, Tehrani-
Doost M, et al. Vitamin D status in children with attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84( Pt A): 84 – 90.
25. Eyles DW, Burne TH, McGrath JJ. Vitamin D, brain development and schizophrenia. Front Neuroanat. 2013; 7:18.
26. Rucklidge JJ, Kaplan BJ. Broad-spectrum micronutrient treatment for ADHD: a systematic review. BMC Psychiatry. 2015; 15:107.
27. Wang Y, Huang L, et al. Vitamin D deficiency and ADHD risk: a review. PLoS One. 2017; 12: e0172682.
28. Mohammadpour N, Jazayeri S, et al. Vitamin D and ADHD symptom severity. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 84:84 – 90.
29. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, hormone regulation and immune – brain interactions. Front Neuroendocrinol. 2009; 30( 2): 263 – 291.
30. Cussotto S, Clarke G, Dinan TG, Cryan JF. Psychotropic drugs and the gut microbiome: implications for psychiatry. Psychopharmacology. 2018; 235( 5): 1519 – 1534.
31. Shirvani-Rad S, Gandomkar M, et al. Gut – brain axis in ADHD: a systematic review. J Atten Disord. 2022; 26( 13): 1558 – 1572. 32. Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. J Steroid Biochem Mol Biol. 2002; 83( 1 – 5): 77 – 85.
33. Tang K, Wang Y, et al. Effect of Dimu Ningshen on gut microbiota and serum metabolomics in ADHD. BMC Complement Med Ther. 2022; 22:233.
34. Shirvani-Rad S, Gandomkar M, et al. Gut microbiota alterations in ADHD: mechanistic insights. J Atten Disord. 2022; 26:1558 – 1572.
35. Cussotto S, et al. Psychotropic – microbiota interactions and metabolic consequences. Psychopharmacology. 2018; 235:1519 – 1534.
36. Weyns A-S, et al. Combined pine bark extract and methylphenidate effects on gut microbiota in ADHD. Front Nutr. 2024; 11:225.
37. Trebatická J, Kopasová S, et al. Treatment of ADHD with French maritime pine bark extract( Pycnogenol): a randomized controlled trial. Eur Child Adolesc Psychiatry. 2006; 15( 6): 329 – 335.
38. Rohdewald P. Review of clinical studies on Pycnogenol. Int J Clin Pharmacol Ther. 2002; 40( 4): 158 – 168.
39. American Academy of Pediatrics. Clinical practice guidelines for the diagnosis and management of ADHD. AAP Guidelines. 2019.
40. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Pediatrics. 2007; 120( 2): e1102 – e1112. 41. Keil MF, Briody JN, Dakin C, et al. Growth and bone density in children receiving stimulant medication for attention-deficit / hyperactivity disorder. Horm Res Paediatr. 2019; 91( 2): 109 – 121.
42. Oner O, Oner P, Cop E, et al. Ferritin levels and their relationship to symptoms of attention-deficit / hyperactivity disorder in children with and without learning disability. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34( 3): 500 – 505. 43. Aarts E, Ederveen THA, Naaijen J, et al. Gut microbiome in attention-deficit / hyperactivity disorder and its relation to neural reward anticipation. PLoS One. 2017; 12( 9): e0176573.
44. Faraone SV, Buitelaar J, Saylor K, et al. Treatment adherence and persistence in patients with ADHD receiving medication management: a meta-analysis. J Am Acad Child Adolesc Psychiatry. 2008; 47( 10): 994 – 1002.
45. Pomeroy SL, Thompson N, Miller S, et al. Bone mineral density in children with ADHD: the influence of stimulant treatment. Bone Res. 2020; 8:29.
46. Weaver CM, Peacock M, Huey J, et al. Interactions of vitamin D, magnesium, and calcium in nutritional regulation of bone health. J Steroid Biochem Mol Biol. 2019; 198:105558.
47. Motyl KJ, Rosen CJ. The unexpected skeletal effects of psychotropic medications. Bone. 2020; 130:115126.
48. Feuer AJ, Demmer RT, Thai JL, et al. Association between stimulant medication use and bone mass in children and adolescents with ADHD. J Pediatr. 2016; 178:260 –
202 | vol31 | no4 | AJNM